Newsroom


New Results for Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

New Results for Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Earlier this week at the European Society of Cardiology Congress in Munich, Germany, Pfizer announced that in patients with transthyretin amyloid cardiomyopathy, Tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life.

Read the entire press release here.